All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2026-04-07.
From the record
Editas Medicine, Inc.'s filings since 2017 show 1 warning event: an auditor change (8-K item 4.01, the latest 2026-04-07) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+14.5% a year over 9 filed years; profitable in 0 of 9.
From the record
Editas Medicine, Inc.'s 9 filed years say what it did: revenue went from $14 million in fiscal 2017 to $41 million in fiscal 2025, up 14.5% a year; it rose in 4 of 8 years; the deepest fall was 78% from fiscal 2020 to fiscal 2022; net income was positive in 0 of 9 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 7.0/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Editas Medicine, Inc.'s shareholder treatment is put at 7.0 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 30% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -587%: lost 587¢ per shareholder dollar. Leverage 85%: owes 85¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Editas Medicine, Inc. lost about 587 cents for every dollar of shareholders' money. Leverage: it owed about 85 cents per dollar of assets, and net share issuance: its share count grew 7.8% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 43% of 102 in its family; net margin -395%.
From the record
Editas Medicine, Inc.'s standing among 102 graded names in its industry family: revenue of $41 million in fiscal 2025 ranks in the top 44% by size; a net margin of -395% ranks in the bottom 45%; revenue growth of 27.1% a year over the last 3 filed years ranks in the top 28% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 32% of 110 in its family for leadership; chief executive since 2022.
From the record
Editas Medicine, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is O'Neill, Gilmore Neil (CEO, as filed), filing under that title since 2022-06-06, 4.4 years (bottom 45% of its family); the 10 officers and directors filing in the last fifteen months have been on the record a median of 4 years (bottom 21%); 7 officer or director changes were reported on Form 8-K since 2023-11-13, against the 10 people in charge now (bottom 31%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
top 47% of 92 in its family for room to expand.
From the record
Editas Medicine, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $147 million against debt of $54 million leaves 49.9% of its assets as net cash, top 33% of its family; cash from operations less capital spending is -409.3% of revenue (bottom 36%); research spending of 222% of revenue (top 43%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 48% of 100 in its family for growth drivers.
From the record
Editas Medicine, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 27.1% a year over the last three filed years against 14.5% over all 9, speeding up (top 14% of its family); the newest year grew 25.4% (top 42%); research spending grew -19.9% a year (bottom 13%); capital spending grew -47.2% a year (bottom 33%) (its annual reports). Editas Medicine, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 45% of 72 in its family for expectations against reality.
From the record
Editas Medicine, Inc.'s newest year against its own record: revenue of $41 million in fiscal 2025 came in 2% below the $41 million its prior three years' pace pointed to (bottom 46% of its family); net income of $160 million against a prior three-year average of $204 million (top 45%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 34%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made